Cytokine release assays: Current practices and future directions

Cytokine

Volumn 66, Issue 2, 2014, Pages 143-155

  Finco, D ^a   Grimaldi, C ^b   Fort, M ^c   Walker, M ^d   Kiessling, A ^e   Wolf, B ^e   Salcedo, T ^f   Faggioni, R ^g   Schneider, A ^g   Ibraghimov, A ^h   Scesney, S ^h   Serna, D ^h   Prell, R ⁱ   Stebbings, R ^j   Narayanan, P K ^c  

^a PFIZER INC   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c AMGEN INC   (United States)

^d JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^e NOVARTIS PHARMA AG   (Switzerland)

^f BRISTOL MYERS SQUIBB   (United States)

^g MEDIMMUNE   (United States)

^h ABBVIE INC   (United States)

ⁱ GENENTECH INC   (United States)

^j NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

more..

Author keywords

Cytokine release assay; Cytokine storm; Monoclonal antibody; TGN 1412

Indexed keywords

CYTOKINE; TGN 1412;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY SCREENING; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOKINE RELEASE ASSAY; CYTOKINE RESPONSE; CYTOKINE STORM; DECISION MAKING; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; IMMUNOASSAY; MEDICAL RESEARCH; NONHUMAN; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

CYTOKINE RELEASE ASSAY; CYTOKINE STORM; MONOCLONAL ANTIBODY; TGN 1412;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIGENS, CD28; BIOLOGICAL ASSAY; CYTOKINES; DRUG EVALUATION, PRECLINICAL; HUMANS; INFLAMMATION; MULTIPLE ORGAN FAILURE;

EID: 84894644075     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2013.12.009     Document Type: Review

References (41)

1. Suntharalingam G., Perry M.E., Ward S., Brett S.J., Castello-Cortes A., Brunner M.D., et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN 1412. NewEngl J Med 2006, 355:1018-1028.
2. Dowsing T., Kendall M.J. The Northwick Park tragedy - protecting healthy volunteers in future first-in-man trials. J Clin Pharm Ther 2007, 32:203-207.
3. Expert Group on Phase One Clinical Trials (Chairman: Professor Gordon W. Duff). Final Report. TSO (The Stationary Office); 2006.
4. European Medicines Agency (EMEA). Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products. EMEA/CHMP/SWP/28367/07; 2007.
5. Vidal J.M., Kawabata T.T., Thorpe R., Silva-Lima B., Cederbrant K., Poole S., et al. In vitro cytokine release assays for predicting cytokine release syndrome: the current state-of-the-science. Report of a European Medicines Agency Workshop. Cytokine 2010, 51:213-215.
6. Stebbings R., et al. 2007 "Cytokine storm" in the Phase I trial of monoclonal antibody TGN 1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2006, 179:3325-3331.
7. Findlay L., Eastwood D., Stebbings E., Sharp G., Mistry Y., Ball C., et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN 1412. J Immunol Meth 2010, 353:1-10.
8. Dhir V., Fort M., Mahmood A., Higbee R., Warren W., Narayanan P., et al. A predictive biomimetic model of cytokine release induced by TGN 1412 and other therapeutic monoclonal antibodies. J Immunotox 2012, 9:34-42.
9. Römer P.S., Berr S., Avota E., Na S.-Y., Berge I., Einsele H., et al. Preculture of PBMC's at high cell density increases sensitivity of T-cell responses, revealing cytokine release by CD28 superagonist TGN 1412. Blood 2011, 118:6772-6782.
10. Wolf B., Morgan H., Krieg J., Gani Z., Milicov A., Warncke M., et al. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. Cytokine 2012, 60:828-837.
11. Findlay L., Sharp G., Fox B., Ball C., Robinson C.J., Bird C., et al. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN 1412 in culture. Cytokine 2011, 55:141-151.
12. Weissmuller S., Semmler L., Kalinke U., Christians S., Muller-Berghaus I., Waibler Z. ICOS-LICOS interaction is critically involved in TGN 1412-mediated T cell activation. Blood 2012, 119:6268-6277.
13. Stebbings R., Eastwood D., Poole S., Thorpe R. After TGN 1412: recent developments in cytokine release assays. J Immunotoxicol 2013, 10:75-82.
14. Wing M.G., Waldmann H., Isaacs J., Compston D.A., Hale G. Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody Isotype. Therapeutic Immunol 1995, 2(4):183-190.
15. Bailey L., Moreno L., Manigold T., Krasniqi S., Kropshofer H., Hinton H., et al. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies. J Pharmacol Toxicol Methods 2012, 68(2):231-239.
16. Robinet E., Morel P., Assossou O., Revillard J.P. TNF- production as an in vitro assay predictive of cytokine-mediated toxic reactions induced by monoclonal antibodies. Toxicology 1995, 100:213-223.
17. Stout D. A requirement for native (undenatured) IgG for detection specificity of the IgG-Fc receptor on lymphocytes. J Immunol Meth. 1981, 40(1):7-16.
18. Eastwood D., Findlay L., Poole S., Bird C., Wadhwa M., Moore M., et al. Monoclonal antibody TGN 1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 2010, 161:512-526.
19. O'Connor R.S., Hao X., Shen K., Bashour K., Akimova T., Hancock W.W., et al. Substrate rigidity regulates human T cell activation and proliferation. J Immunol 2012, 189:1330-1339.
20. Findlay L. Development of in vitro procedures that can better predict the safety of therapeutic monoclonal antibodies. Masters Thesis, University College London; 2012.
21. Walker M., Makropoulos D., Achuthanandam R., Van Arsdell S., Bugelski P. Development of a human whole blood assay for prediction of cytokine release similar to Anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis. Int Immunopharmacol 2011, 11:1697-1705.
22. Jager M., Schoberth A., Hess J., Lindhofer H. The trifunctional antibody ertumaxomab destroys tumor cells that express low levels of human epidermal growth factor receptor 2. Cancer Res 2009 May 15, 69(10):4270-4276.
23. Suchard S., Davis P., Kansal S., Stetsko D., Brosius R., et al. A monovalent anti-human CD28 domain antibody antagonist: preclinical efficacy and safety. J Immunol 2013, 191:4599-4610.
24. Lowe P., Tannenbaum S., Wu Kai, Lloyd P., Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol 2009, 106:195-209.
25. Muller P.Y., Brennan F.R. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 2009, 85:247-258.
26. Muller P.Y., Milton M., Lloyd P., Sims J., Brennan F.R. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Current Opin Biotechnol 2009, 20:722-729.
27. Rascu A., Repp R., Westerdaal N.A.C., Kalden J., VanDe Winkel J.G.J. Clinical relevance of Fcγ receptor polymorphisms. Ann NY Acad Sci 2007, 815:282-295.
28. Eastwood D., Bird C., Dilger P., Findlay L., Poole S., Thorpe S.J., et al. Severity of the TGN1412 trial disaster cytokine storm correlated with IL-2 release. Brit J Clin Pharmacology 2013, 76(2):299-315.
29. Wolf B., Morgan H., Brennan F., Krieg J., Gani Z., Jones S., et al. Response to the Letter to the Editor by Susan Thorpe et al.: how predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine 2013, 64:473-475.
30. Thorpe S.J., Stebbings R., Findlay L., Eastwood D., Poole S., Thorpe R. How predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine 2013, 64:471-472.
31. Thorpe S.J., Stebbings R., Findlay L., Eastwood D., Poole S., Thorpe R. Reply to the response from Babette Wolf et al. to our Letter to the Editor: how predictive are in vitro assays for cytokine release syndrome in vivo? A comparison of methods reveals worrying differences in sensitivity and frequency of response. Cytokine 2013, 64:476.
32. Keown P., Decamps B. Suppression of the mixed lymphocyte reaction by autologous red cells and their constituents: a new hypothesis on the apparent tolerogeneic effect of blood transfusions during transplantation. C R Acad Sci Hebd Seances cad Sci D 1978, 287:749-752. (article in French).
33. Keown P., Descamps-Latscha B. In vitro suppression of cell-mediated immunity by ferroproteins and ferric salts. Cell Immunol 1983, 80:257-266.
34. Butler J.E., Ni L., Brown W.R., Joshi K.S., Chang J., Rosenburg B., et al. The immunochemistry of sandwich ELISAs-greater than 90% of monoclonal and 75% of polyclonal anti-fluorescyl capture antibodies (Cabs) are denatured by passive adsorption. Mol Immunol 1993, 13:1165-1175.
35. Kirton C.M., Gliddon D.R., Bannish G., Bembridge G.P., Coney L.A. In vitro cytokine release assays: reducing the risk of adverse events in man. Bioanalysis 2011, 3:2657-2663.
36. Findlay L., Eastwood D., Ball C., Robinson C.J., Bird C., Wadhwa M., et al. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy. J Immunol Methods 2011, 371:134-142.
37. Friqualt M., June C. Predicting cytokine storms: it's about density. Bood 2011, 118:6724-6726.
38. Bevan M.J., Memory T. Cells as an occupying force. Eur J Immunol 2011, 41:1192-1195.
39. Hunig T. The Storm has cleared: lessons from the CD28 superagonist TGN 1412 Trial. Nat Rev Immunol 2012, 12:317.
40. Stefanova I., Dorfman J., Germain R. Self-recognition promotes the foreign antigen sensitivity of naïve T lymphocytes. Lett Nat 2002, 420:429-434.
41. Wadhwa M., Thorpe R. Standardization and calibration of cytokine immunoassays: meeting report and recommendations. Cytokine 1997, 9(11):791-793.